Ogren S O
Acta Psychiatr Scand Suppl. 1986;329:13-27.
Studies in mice demonstrated that the anticonvulsant profile of chlormethiazole differs from that of diazepam and the barbiturates. Chlormethiazole protects animals from convulsions induced by a wide variety of chemoconvulsants known to block the action of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), such as bicuculline, picrotoxin, isoniazid and pentetrazol, thus confirming and extending earlier studies on its broad anticonvulsant characteristics. Chlormethiazole is particularly potent against isoniazid-induced convulsions, which are probably induced by reductions of GABA levels in the brain. Chlormethiazole was found to have a weak action on benzodiazepine receptor binding, GABA receptor binding and kainic acid receptor binding. Chlormethiazole inhibited picrotoxin binding at very high concentrations, but lowered the functional effects of picrotoxin at much lower concentrations than those affecting picrotoxin binding. Moreover, chlormethiazole failed to change GABA or glutamate levels in the brain and did not affect glutamic acid decarboxylase (GAD) activities in the rat brain. Muscimol (a GABAA agonist) enhanced the anticonvulsant activity of chlormethiazole against picrotoxin but not against bicuculline-induced convulsions. Muscimol enhanced the anticonvulsant potency of diazepam against both chemoconvulsants. These data suggest that the anticonvulsant activity of chlormethiazole is not mediated directly through changes in GABA or glutamate levels or by a direct (agonist) action at the GABA or benzodiazepine receptor complex. These findings suggest that chlormethiazole may enhance GABA transmission beyond the GABA receptors, hypothetically at the level of the GABA receptor coupled ionophore (e.g. the chloride ion channel). Applied micro-iontophoretically, chlormethiazole was found to potentiate the inhibitory responses to GABA, muscimol and glycine, but not to acetylcholine. The potentiation of glycine-mediated inhibition is unique for chlormethiazole and does not occur with any other known anticonvulsant (barbiturates, benzodiazepine, phenytoin or sodium valproate). Studies in primary cultures, derived from spinal cord neurones, showed that chlormethiazole produces hyperpolarization together with an increase in the threshold for action potential generation. Further in vitro studies indicated that chlormethiazole acts on some types of Ca2+-dependent chloride ion channels.(ABSTRACT TRUNCATED AT 400 WORDS)
对小鼠的研究表明,氯美噻唑的抗惊厥特性与地西泮和巴比妥类药物不同。氯美噻唑能保护动物免受多种已知可阻断抑制性神经递质γ-氨基丁酸(GABA)作用的化学惊厥剂诱发的惊厥,如荷包牡丹碱、印防己毒素、异烟肼和戊四氮,从而证实并扩展了早期关于其广泛抗惊厥特性的研究。氯美噻唑对异烟肼诱发的惊厥特别有效,而异烟肼诱发的惊厥可能是由大脑中GABA水平降低引起的。研究发现氯美噻唑对苯二氮䓬受体结合、GABA受体结合和 kainic 酸受体结合的作用较弱。氯美噻唑在非常高的浓度下能抑制印防己毒素结合,但在比影响印防己毒素结合的浓度低得多的浓度下就能降低印防己毒素的功能作用。此外,氯美噻唑未能改变大脑中的GABA或谷氨酸水平,也不影响大鼠脑中的谷氨酸脱羧酶(GAD)活性。蝇蕈醇(一种GABAA激动剂)增强了氯美噻唑对印防己毒素的抗惊厥活性,但对荷包牡丹碱诱发的惊厥无效。蝇蕈醇增强了地西泮对这两种化学惊厥剂的抗惊厥效力。这些数据表明,氯美噻唑的抗惊厥活性不是直接通过GABA或谷氨酸水平的变化,也不是通过对GABA或苯二氮䓬受体复合物的直接(激动剂)作用介导的。这些发现表明,氯美噻唑可能在GABA受体之外增强GABA传递,推测是在GABA受体偶联离子载体(如氯离子通道)水平。通过微离子电泳应用发现,氯美噻唑能增强对GABA、蝇蕈醇和甘氨酸的抑制反应,但对乙酰胆碱无效。氯美噻唑对甘氨酸介导的抑制的增强作用是其独特之处,其他任何已知的抗惊厥药(巴比妥类、苯二氮䓬类、苯妥英或丙戊酸钠)都不会出现这种情况。对源自脊髓神经元的原代培养物的研究表明,氯美噻唑会产生超极化,并伴随着动作电位产生阈值的增加。进一步的体外研究表明,氯美噻唑作用于某些类型的钙依赖性氯离子通道。(摘要截取自400字)